Geron (GERN) Cash from Operations (2010 - 2026)
Geron's (GERN) quarterly Cash from Operations came in at -$15.8 million in Q2 2026, up 42.27% year-over-year from -$11.1 million in Q2 2025, and up 74.84% quarter-over-quarter from -$62.9 million in Q1 2026.
Analysis
Geron (GERN) Cash from Operations (2010 - 2026) Analysis & Trends
Geron has disclosed Cash from Operations across 17 years of filings, most recently posting -$15.8 million for Q2 2026.
- In Q2 2026, Cash from Operations rose 42.27% year-over-year to -$15.8 million; the TTM figure through Jun 2026 stood at -$114.4 million (up 35.85% YoY), while the FY2025 annual figure was -$111.0 million, up 49.21% from the prior year.
- Cash from Operations came in at -$15.8 million for Q2 2026 at Geron, up from -$62.9 million in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of -$13.6 million in Q3 2025 to a low of -$62.9 million in Q1 2026.
- Average Cash from Operations over 5 years is -$39.1 million, with a median of -$38.1 million recorded in 2022.
- Year-over-year, Cash from Operations tumbled 80.66% in 2024 and jumped 76.97% in 2025.
- Over 5 years, Cash from Operations stood at -$35.2 million in 2022, then retreated by 16.36% to -$40.9 million in 2023, then fell by 7.35% to -$43.9 million in 2024, then jumped by 49.78% to -$22.1 million in 2025, then rose by 28.28% to -$15.8 million in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were -$15.8 million in Q2 2026, -$62.9 million in Q1 2026, and -$22.1 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 4.00 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 3.57 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.13 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 813.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -526.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 448.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -270.50 Mn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | -15.83 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.83 Mn |
| Mar 31, 2026 | -62.91 Mn |
| Dec 31, 2025 | -22.07 Mn |
| Sep 30, 2025 | -13.58 Mn |
| Jun 30, 2025 | -27.42 Mn |
| Mar 31, 2025 | -47.98 Mn |
| Dec 31, 2024 | -43.95 Mn |
| Sep 30, 2024 | -58.94 Mn |
| Jun 30, 2024 | -53.48 Mn |
| Mar 31, 2024 | -62.25 Mn |
| Dec 31, 2023 | -40.94 Mn |
| Sep 30, 2023 | -50.84 Mn |
| Jun 30, 2023 | -29.60 Mn |
| Mar 31, 2023 | -46.37 Mn |
| Dec 31, 2022 | -35.18 Mn |
| Sep 30, 2022 | -29.58 Mn |
| Jun 30, 2022 | -28.64 Mn |
| Mar 31, 2022 | -33.97 Mn |
| Dec 31, 2021 | -22.17 Mn |
| Sep 30, 2021 | -22.84 Mn |